申聯生物(688098.SH):實控人之一、董事長聶東昇提議回購股份 資金總額不超過4000萬元
格隆匯11月24日丨申聯生物(688098.SH)發佈公吿,公司董事會於2024年11月22日收到公司實際控制人之一、董事長聶東昇遞交的《關於提議申聯生物醫藥(上海)股份有限公司回購公司股份的函》,聶東昇提議公司通過集中競價交易方式回購公司已發行的部分人民幣普通股(A股)股票,回購股份的資金總額不低於人民幣2000萬元(含),不超過人民幣4000萬元(含),具體以董事會審議通過的回購股份方案為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.